Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q15020
UPID:
SART3_HUMAN
Alternative names:
Tat-interacting protein of 110 kDa; p110 nuclear RNA-binding protein
Alternative UPACC:
Q15020; A8K2E4; B7ZKM0; Q2M2H0; Q58F06; Q8IUS1; Q96J95
Background:
Squamous cell carcinoma antigen recognized by T-cells 3, also known as Tat-interacting protein of 110 kDa or p110 nuclear RNA-binding protein, plays a pivotal role in the splicing machinery of cells. It functions as a recycling factor for U4 and U6 snRNPs, essential for spliceosome maturation and U12-type spliceosomal complex assembly. This protein is also involved in deubiquitination processes, targeting PRPF3 within the U4/U5/U6 tri-snRNP complex and histone H2B, thereby influencing gene expression and DNA repair.
Therapeutic significance:
Understanding the role of Squamous cell carcinoma antigen recognized by T-cells 3 could open doors to potential therapeutic strategies.